Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ascendis Pharma A/S ASND

Healthcare Biotechnology
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ASND)

Ascendis Pharma Reports Third Quarter 2024 Financial Results

GlobeNewswire 9 days ago

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

GlobeNewswire November 7, 2024

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

GlobeNewswire November 4, 2024

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon(TM) PTH (Palopegteriparatide) Presented at ASBMR 2024

GlobeNewswire September 30, 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon(TM) hGH for the Treatment of Adults with Growth Hormone Deficiency

GlobeNewswire September 30, 2024

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

GlobeNewswire September 19, 2024

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

GlobeNewswire September 18, 2024

Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

GlobeNewswire September 16, 2024

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

GlobeNewswire September 13, 2024
View More News ››

Opinion & Analysis (NDAQ:ASND)

VIDEO: Ascendant Resources: Production Numbers Of Q3 2017

Commodity-TV October 19, 2017
View More Opinion ››

Bullboard Posts (NDAQ:ASND)

ASND Price Target Alert: $200.00. Issued by Goldman Sachs

Breaking News: $ASND ASND Price Target Alert: $200.00. Issued by Goldman Sachs2024-09-16 15:00:05 ET Paul Choi from Goldman Sachs issued...
whytestocks - September 16, 2024

Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) A

JUST IN: $ASND Pivotal ApproaCH Trial of TransCon(TM) CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to...
whytestocks - September 16, 2024

Ascendis to Present First Results from Platinum-Resistant Ov

JUST IN: $ASND Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial...
whytestocks - September 13, 2024
View more Bullboard ››

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc. is a Canada-based exploration and mining company. The Company is focused on nickel, copper, and ...
View More »